<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> syndrome (APS) is now recognized as one of the most important causes of <z:hpo ids='HP_0100724'>hypercoagulability</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The most common site for <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> in APS is <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> of the lower extremities </plain></SENT>
<SENT sid="2" pm="."><plain>Other sites of <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> include <z:chebi fb="46" ids="15035">retinal</z:chebi> veins, renal veins, and hepatic veins </plain></SENT>
<SENT sid="3" pm="."><plain>The authors report a case of splenic vein <z:mp ids='MP_0005048'>thrombosis</z:mp> disclosing <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> in which also the cytolytic effect of aPL may play a role of "cofactor" in the genesis of <z:mp ids='MP_0005048'>thrombosis</z:mp> through the release of thromboplastin from the lysis of red cells, granulocytes and platelets, making them vulnerable to clearance by splenic macrophages </plain></SENT>
<SENT sid="4" pm="."><plain>Important considerations are stressed about differential diagnosis, etiopathogenetic factors, therapy and follow-up of the patient </plain></SENT>
</text></document>